drugset / Trial / NCT00664365

FTIH Study With GSK958108

NCT00664365 ↗

Phase 1 Completed 21 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

This study is the first administration of GSK958108 to man. The study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK958108 and evaluate the effect of food on GSK958108 pharmacokinetics

Timeline

Start
2008-04-12
Primary completion
2008-08-22
Completion
2008-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK958108 Small molecule 1 mg Oral
Subject GSK958108 Small molecule 5 mg Oral
Subject GSK958108 Small molecule 25 mg Oral
Subject GSK958108 Small molecule 50 mg Oral

Indications